http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html si-local-file:///var/storage/secattach/20260623/26679668.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html Tue, 23 Jun 2026 16:16:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html si-local-file:///var/storage/secattach/20260623/26679668.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html Tue, 23 Jun 2026 16:16:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html si-local-file:///var/storage/secattach/20260623/26679668.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Jun+23/26679668.html Tue, 23 Jun 2026 16:16:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/Corporate+News/FDA+conditionally+approves+QYLEKI+as+brand+name+for+Quoin+drug/26676472.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has conditionally approved QYLEKI as the proposed brand name for QRX003, its investigational topical treatment for Netherton Syndrome, a rare inherited skin disorder with no currently approved therapies.</p><p>The conditional approval of the brand name, pronounced "Key-Lek-ee," was developed in accordance with FDA guidance on proprietary names. Final approval of the QYLEKI brand name will be contingent on FDA marketing approval of QRX003. A request for proprietary name review and final approval will be included in a future New Drug Application.</p><p>QRX003 holds Orphan Drug Designation in the United http://www.streetinsider.com/Corporate+News/FDA+conditionally+approves+QYLEKI+as+brand+name+for+Quoin+drug/26676472.html Tue, 23 Jun 2026 08:31:27 -0400 QNRX http://www.streetinsider.com/FDA/FDA+conditionally+approves+QYLEKI+as+brand+name+for+Quoin+drug/26676472.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has conditionally approved QYLEKI as the proposed brand name for QRX003, its investigational topical treatment for Netherton Syndrome, a rare inherited skin disorder with no currently approved therapies.</p><p>The conditional approval of the brand name, pronounced "Key-Lek-ee," was developed in accordance with FDA guidance on proprietary names. Final approval of the QYLEKI brand name will be contingent on FDA marketing approval of QRX003. A request for proprietary name review and final approval will be included in a future New Drug Application.</p><p>QRX003 holds Orphan Drug Designation in the United http://www.streetinsider.com/FDA/FDA+conditionally+approves+QYLEKI+as+brand+name+for+Quoin+drug/26676472.html Tue, 23 Jun 2026 08:31:27 -0400 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html <ul type="disc"><li style="margin-bottom:4pt;"><em>QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA</em></li><li style="margin-bottom:4pt;"><em>Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027</em></li><li style="margin-bottom:4pt;"><em>Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16</em></li><li style="margin-bottom:14pt;"><em>QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome</em></li></ul> <p>ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+Conditional+Approval+of+QYLEKI%E2%84%A2+as+the+Proposed+Brand+Name+for+QRX003+for+Netherton+Syndrome/26676438.html Tue, 23 Jun 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Corporate+News/Quoin+Pharma+forms+Japan+subsidiary+to+advance+QRX003+commercialization/26663333.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has established a wholly-owned subsidiary in Japan as part of its plan to directly commercialize QRX003, a treatment candidate for Netherton Syndrome, if the drug receives regulatory approval.</p><p>The subsidiary formation follows Japan's Ministry of Health, Labour and Welfare granting Orphan Drug Designation to QRX003. The drug has now received Orphan Drug Designation in the United States, the European Union, and Japan — covering all three of Quoin's core commercial territories.</p><p>Japan joins the U.S. and Western Europe as markets where Quoin intends to self-commercialize QRX003. The company previously established Quoin Therapeutics Ireland as its Western European http://www.streetinsider.com/Corporate+News/Quoin+Pharma+forms+Japan+subsidiary+to+advance+QRX003+commercialization/26663333.html Thu, 18 Jun 2026 08:31:44 -0400 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Completes+Establishment+of+Japanese+Subsidiary+to+Advance+Commercial+Readiness+for+QRX003/26663272.html <p><em>Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories</em></p> <p><em>Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW</em></p> <p>ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation follows the recent grant of Orphan http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Completes+Establishment+of+Japanese+Subsidiary+to+Advance+Commercial+Readiness+for+QRX003/26663272.html Thu, 18 Jun 2026 08:30:00 -0400 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Completes+Establishment+of+Japanese+Subsidiary+to+Advance+Commercial+Readiness+for+QRX003/26663272.html <p><em>Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories</em></p> <p><em>Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW</em></p> <p>ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation follows the recent grant of Orphan http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Completes+Establishment+of+Japanese+Subsidiary+to+Advance+Commercial+Readiness+for+QRX003/26663272.html Thu, 18 Jun 2026 08:30:00 -0400 QNRX http://www.streetinsider.com/Corporate+News/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported that four of six pediatric patients enrolled in its Netherton Syndrome (NS) compassionate use program showed improvement from baseline across key clinical endpoints, according to a press release dated June 16, 2026.</p><p>All six patients are under 10 years of age, with the youngest being six months old. Treatment duration ranges from three weeks to 15 months. No treatment-related adverse events have been reported for any of the six patients.</p><p>Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved http://www.streetinsider.com/Corporate+News/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html Tue, 16 Jun 2026 08:31:32 -0400 2EB0 QNRX http://www.streetinsider.com/Corporate+News/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported that four of six pediatric patients enrolled in its Netherton Syndrome (NS) compassionate use program showed improvement from baseline across key clinical endpoints, according to a press release dated June 16, 2026.</p><p>All six patients are under 10 years of age, with the youngest being six months old. Treatment duration ranges from three weeks to 15 months. No treatment-related adverse events have been reported for any of the six patients.</p><p>Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved http://www.streetinsider.com/Corporate+News/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html Tue, 16 Jun 2026 08:31:32 -0400 2EB0 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported that four of six pediatric patients enrolled in its Netherton Syndrome (NS) compassionate use program showed improvement from baseline across key clinical endpoints, according to a press release dated June 16, 2026.</p><p>All six patients are under 10 years of age, with the youngest being six months old. Treatment duration ranges from three weeks to 15 months. No treatment-related adverse events have been reported for any of the six patients.</p><p>Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+4+of+6+patients+improved+in+NS+compassionate+use+trial/26651052.html Tue, 16 Jun 2026 08:31:32 -0400 2EB0 QNRX